Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.

Authors :: Quintino de Oliveira B
Catto LFB
Santana BAA
Tellechea MF
Scheucher PS
Scheinberg P
Calado RT
Source :: British journal of haematology [Br J Haematol] 2021 Apr; Vol. 193 (2), pp. 410-414. Date of Electronic Publication: 2020 Nov 20.
Publication Year :: 2021
Abstract: Eltrombopag has been added to first-line treatment of immune aplastic anaemia (AA), resulting in higher responses. We analysed marrow samples of AA patients who responded to immunosuppressive therapy (IST) alone or in combination with eltrombopag for the composition of the haematopoietic stem and progenitor cell (HSPC) compartment. The number of CD34 <superscript>+</superscript> cells and multipotent progenitors was higher in patients treated with eltrombopag (P < 0·005; P < 0·05; respectively), but not the number of stem cells. No aberrant phenotype was observed. These results indicate that eltrombopag augments CD34 <superscript>+</superscript> cells in vivo and preferentially expands multipotent progenitors, but not stem cells.<br /> (© 2020 British Society for Haematology and John Wiley & Sons Ltd.)

Full Text Access

Tools